AI assistant
Active Biotech — Board/Management Information 2011
Mar 15, 2011
3133_rns_2011-03-15_0055226f-7530-4caf-96af-3d68e691cf2d.pdf
Board/Management Information
Open in viewerOpens in your device viewer
PRESS RELEASE
Helén Tuvesson appointed as new Chief Scientific Officer at Active Biotech
Dr. Helén Tuvesson takes up the post as Chief Scientific Officer within Active Biotech from April 1, 2011. Helén Tuvesson will be reporting to Tomas Leanderson, President & CEO.
Dr. Tuvesson has worked in the pharmaceutical industry for more than 20 years and has extensive experience in drug development, from the early preclinical stage up to late clinical development. Helén has been on different positions within Active Biotech since 1998, most recently as Head of the department of Preclinical Development. She has been a member of the R&D management for three years, and the recent year also in the senior management team at Active Biotech.
The appointment will strengthen Active Biotech's R&D capabilities going forward after the recent positive results obtained in the laquinimod and TASQ clinical studies.
Lund, March 15, 2011 Active Biotech AB (publ)
For further information, please contact:
Tomas Leanderson Tel: +46 (0)46 19 20 95 E-mail: [email protected]
About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in or entering pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, TASQ for prostate cancer and ANYARA for use in cancer targeted therapy, primarily of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn's and Lupus. Further projects in clinical development comprise the two orally administered compounds, 57- 57 for SLE and Systemic Sclerosis as well as RhuDexTM for RA. Please visit www.activebiotech.com for more information.
Active Biotech AB PO Box 724, SE-220 07 Lund Sweden Tel: +46 (0)46-19 20 00 Fax: +46 (0)46-19 11 00
Active Biotech is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 3:00 pm CET on March 15, 2011.